~ PEDMARK® Net Product Revenue of $6.5 Million, a 96% Increase Compared to Second Quarter ~ ~ Strong Commercial Uptake Underscoring Significant Unmet Medical Need ~ ~ Received Approval in October.
Fennec Pharmaceuticals (NASDAQ:FENC) vs Kiromic BioPharma (NASDAQ:KRBP) Head-To-Head Contrast theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2023 Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter.
/PRNewswire/ Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr..